Navigation Links
Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study
Date:5/21/2013

SAN DIEGO, May 21, 2013 /PRNewswire/ -- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin). CERE-120 is a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.  This exploratory analysis identified a more robust response to CERE-120 in Parkinson's patients diagnosed within 5 years prior to treatment relative to those diagnosed 10 years or more (p<.005), as measured by change from baseline on the Unified Parkinson's Disease Rating Scale or (UPDRS) motor-off, the primary endpoint for this study. Previously Ceregene reported that the primary endpoint (UPDRS) was not met for the overall study population, although one of the 3 prescribed 'key secondary endpoints' (Diary-hours off) did demonstrate statistical significance and no safety issues were identified.  In addition to CERE-120 favorably impacting the UPDRS motor-off scale in patients treated within 5 years of diagnosis, additional exploratory analyses revealed similar improvement for the same patients in other important Parkinson's disease measurements, including the PDQ-39 (a measure of quality of life) and patient's daily diaries (computing hours "on without troubling dyskinesias").

Raymond T. Bartus , Ph.D., executive vice president and chief scientific officer of Ceregene stated: "The concept that earlier-stage patients may respond better to neurotrophic factor therapies such as CERE-120 is consistent with the field's long-standing appreciation for their mechanism of action, as well as more recent information derived from autopsy brain tissue donated by Parkinson's disease patients. While a number of practical considerations will have to be addressed in order to design and execute clinical trials that enroll only early-stage patients, this additional exploratory
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
2. Ceregene And Alzheimers Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 ... senkt die Leistungsfähigkeit enorm. Es ist schwierig konzentriert ... wacht zum falschen Zeitpunkt in einem Hotelzimmer auf, ... später, nach Hause zurückgekehrt, fühlt man sich  oft ... oder dem Partner etwas zu unternehmen oder bei ...
(Date:5/26/2015)... , May 26, 2015  The National Association of ... pleased to announce that general availability for the .pharmacy ... pharmacies and pharmacy-related entities may apply for .pharmacy domain ... launched in 2014, and NABP has approved more than ... prior limited registration periods. NABP created the .pharmacy TLD ...
(Date:5/26/2015)... Mass. , May 26, 2015  Haemonetics Corporation ... Gould , Vice President, Investor Relations, will present at ... Boston on June 4 th , 2015 ... may access Mr. Gould,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
Breaking Medicine Technology:Jetlag schneller überwinden! Spitzen-Athleten wissen wie: Doppelt so schnell voll leistungsfähig sein mit innovativer Technik 2Jetlag schneller überwinden! Spitzen-Athleten wissen wie: Doppelt so schnell voll leistungsfähig sein mit innovativer Technik 3Jetlag schneller überwinden! Spitzen-Athleten wissen wie: Doppelt so schnell voll leistungsfähig sein mit innovativer Technik 4General Availability for .Pharmacy Domain Names Begins June 3, 2015 2
... Pharmatek Laboratories, Inc., a premier contract development and ... it has added spray drying to its drug ... a Buchi B-290 Mini Spray Dryer for formulation ... can be used for both oral and parenteral ...
... April 25, 2011 Stereotaxis, Inc. (NASDAQ: STXS ... following investor conferences during May 2011: The ... Kaminski, President and Chief Executive Officer of Stereotaxis, is scheduled ... 3, 2011 at 4:10 p.m. ET. The JMP Securities ...
Cached Medicine Technology:Pharmatek Laboratories Adds Spray Drying to Drug Development Services 2Stereotaxis to Present at Upcoming Investor Conferences 2Stereotaxis to Present at Upcoming Investor Conferences 3
(Date:5/27/2015)... The Case Management Society of America ... CMSA Lifetime Achievement Award, to Anne Llewellyn RN-BC, MS, ... 25th at the association’s 25th Annual Conference and Expo ... The CMSA Board of Directors awards the Lifetime Achievement ... significant contribution to practice of case management and in ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 This year, ... health awareness campaign and encouraging those affected to seek assistance ... Mental Health (NAMI), one in five children, ages 13 ... illness. Additionally, 50% of all cases of mental illness within ... suggesting, it is essential to seek help before reaching a ...
(Date:5/27/2015)... According to research conducted by Dr. Huay-Zong ... Dallas some migraine patients have an increased likelihood of ... apparently also have some shared risk factors -- particularly ... a history of diabetes and/or smoking. Both conditions were ... in particular was less common in Hispanics. , ...
(Date:5/26/2015)... 27, 2015 Avid Collector, Andrew ... search for original Jimi Hendrix January 11-23, 1969 psychedelic German ... "medusa" image of Hendrix for this concert poster ... is also known as the Hendrix with wired ... over twelve days. The tour started at the ...
(Date:5/26/2015)... 2015 Degeneration of the white matter ... specific types of Alzheimer’s disease (AD), including early-onset AD, ... the journal Radiology. , “Alzheimer’s is a gray ... the study conducted at the Neuroimaging Research Unit, San ... damage has a central role in how the disease ...
Breaking Medicine News(10 mins):Health News:CMSA to Present Prestigious Lifetime Achievement Award to Anne Llewellyn RN-BC, MS, BHSA, CCM, CRRN 2Health News:The Glenholme School Observes Mental Health Awareness Month 2Health News:The Glenholme School Observes Mental Health Awareness Month 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 2Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 4Health News:Avid Collector from Vintage Rock Posters Announces His Search for Original Jimi Hendrix January 11-23, 1969 Psychedelic German Concert Tour Posters 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3
... Mo. Young adults between the ages of 18 and ... according to the National Survey on Drug Use & Health. ... rural adolescents who engage in prosocial behaviors, such as volunteering ... young adults. Gustavo Carlo, Millsap Professor of Diversity in ...
... -- Men are less likely to drink, use tobacco or ... study. It included more than 200 at-risk males who ... studies have found that marriage can reduce men,s negative behavior, ... This study found that fatherhood was independently associated with ...
... about painful jaw problems that plague millions of Americans are ... results, from the first large-scale clinical study of its kind, ... as TMD. The findings, published in the November ... to new methods of diagnosing facial pain conditions, predicting who ...
... HOUSTON - When given alongside radiation therapy for head ... time to reduce the debilitating side effect of xerostomia, ... MD Anderson Cancer Center and Fudan University Shanghai Cancer ... Cancer , reported findings from the first randomized controlled ...
... that people who develop jaw pain disorders exhibit specific ... and noises in the jaw, more headaches and generally ... UB School of Dental Medicine researchers who are international ... have developed through international collaborations many of the most ...
... how the sense of smell changes as people age, found ... an unexpected response to odor that made it more difficult ... dangerous chemicals and poor nutrition. "We found ... those 60 and up," said Professor Diego Restrepo, Ph.D., director ...
Cached Medicine News:Health News:Volunteering, helping others decreases substance use in rural teens, MU study finds 2Health News:Fatherhood May Help Tough Guys Straighten Out 2Health News:Large-scale jaw pain study sheds light on pain disorders 2Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 2Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 3Health News:First large-scale study of pain reveals risk factors 2Health News:First large-scale study of pain reveals risk factors 3Health News:Researcher finds elderly lose ability to distinguish between odors 2
Indications For Usage:, ,Single use on tracheostomy patients who can breathe spontaneously. The product is intended to be replaced at least once every 24 hours....
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Medicine Products: